Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2026
Reporting Period: Fiscal Year 2026 (ending December 31, 2026)
Context: The filing serves as a Regulation FD disclosure regarding upcoming investor meetings scheduled between March 2, 2026, and March 31, 2026, where management intends to reaffirm its full-year financial guidance.
Key Financial Metrics
The filing focuses exclusively on forward-looking earnings per share (EPS) guidance for FY 2026. No historical revenue, profit, cash flow, margin, debt, or liquidity figures are provided in this specific document.
- GAAP Diluted EPS Guidance (FY 2026): At least $8.89
- Adjusted (Non-GAAP) EPS Guidance (FY 2026): At least $9.00
- Reconciliation Items:
- Amortization of identifiable intangibles: $0.15
- Cumulative net tax impact: $(0.04)
Material Changes Versus Prior Period
The filing states that the current guidance is consistent with the guidance issued in the press release dated February 11, 2026. No material changes to the guidance figures are reported in this document.
Guidance, Outlook, and Risks
Management Commentary: Management utilizes Adjusted (non-GAAP) EPS to provide a comprehensive perspective on core operating performance, planning, and incentive compensation. They believe this measure allows for more accurate period-to-period analysis.
Outlook and Contingencies:
- The Company does not expect changes to its FY 2026 Adjusted (non-GAAP) EPS guidance.
- The Company expects potential changes to its FY 2026 GAAP EPS guidance due to ongoing value creation and other strategic initiatives.
- Guidance excludes the impact of future value changes to items not yet recognized or reasonably estimable.
Risks: The document includes a standard cautionary statement noting that forward-looking statements are subject to risks, uncertainties, and assumptions detailed in the "Risk Factors" section of other SEC filings.
Investor Verification Checklist
- Verify the consistency of the $8.89 GAAP and $9.00 Adjusted EPS guidance against the February 11, 2026, press release.
- Review the "Risk Factors" section in Humana's most recent 10-K or 10-Q to understand specific risks affecting the forward-looking statements.
- Monitor future filings for updates to GAAP EPS guidance, as management explicitly anticipates potential changes due to strategic initiatives.
- Confirm the reconciliation methodology for Adjusted EPS to ensure alignment with the company's historical non-GAAP reporting standards.